📄 Read the full study link.springer.com/article/10.1...

While albendazole showed strong efficacy against hookworm (94.1% egg reduction), it performed poorly against Trichuris trichiura (just 31%).

This highlights the urgent need for updated treatment approaches that are effective across all STH species.

Since then, several studies, clinical trials, and partnerships have shaped the development of our fixed-dose combination of #ivermectin & #albendazole. Want to see how far we’ve come?

📖 Explore the full scientific timeline here 👉 stop2030.org/publications/

This effort, carried out by the STOP2030 Consortium, aims to improve how diseases affecting more than 1.5 billion people are tackled, and to help endemic countries reach their control targets.

Alejandro Krolewiecki, our PI, will give a pitch on the innovations behind the combination of these two drugs: a new dosing strategy that simplifies logistics, enabling the control of more species with equal or lower effort, all in a one-per-person tablet that dissolves on contact with saliva.

Under the REALISE study, we aim to treat ~20,000 people in Ghana and Kenya, thanks to our partners from the Ghana Health Service and KEMRI. The evidence we obtain will be crucial to advancing the FDC and making it available to countries around the world.

Patients in several schools have started receiving treatment, either the FDC or (in the control group) single-dose albendazole. Several years of collaborative work are behind this significant moment for our Consortium.